Document Detail

Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
MedLine Citation:
PMID:  15743103     Owner:  NLM     Status:  MEDLINE    
Since their introduction into clinical practice, somatostatin analogs have been the pharmacological therapy of choice for the treatment of acromegaly. The first preparations of somatostatin analogs available for clinical use were administered subcutaneously two or three times daily, which was not optimal with respect to patient compliance. The introduction of long-acting formulations of somatostatin analogs has overcome this inconvenience. Lanreotide Autogel, a new viscous, supersaturated, aqueous solution of lanreotide, is available in a prefilled syringe and administered by deep subcutaneous injection every 28 days. Lanreotide Autogel has different pharmacokinetic properties from the earlier lanreotide slow-release (SR) formulation, which may account for its better tolerability. Furthermore, lanreotide Autogel is at least as efficacious as the other somatostatin analogs in lowering growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in the majority and in restoring safe GH and age-normalized IGF-1 levels in about 50-60% of patients with acromegaly. In conclusion, lanreotide Autogel is a valuable new addition to the acromegaly treatment armamentarium. Patients receiving intramuscular lanreotide SR injections every 7-14 days can be switched to an appropriate dose of deep subcutaneous lanreotide Autogel every 28 days, without any impact on safety or loss of efficacy.
Antonio Ciccarelli; Adrian Daly; Albert Beckers
Related Documents :
15134303 - Optimization of treatment in turner's syndrome.
17873743 - Effect of long-term low-dose prednisone on height velocity and disease activity in pedi...
23229693 - A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilat...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Treatments in endocrinology     Volume:  3     ISSN:  1175-6349     ISO Abbreviation:  Treat Endocrinol     Publication Date:  2004  
Date Detail:
Created Date:  2005-03-03     Completed Date:  2005-03-17     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  101132977     Medline TA:  Treat Endocrinol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  77-81     Citation Subset:  IM    
Department of Endocrinology, University of Liège, Liège, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acromegaly / blood,  drug therapy*
Human Growth Hormone / blood
Injections, Subcutaneous
Insulin-Like Growth Factor I / analysis
Peptides, Cyclic / administration & dosage*,  pharmacokinetics,  pharmacology
Somatostatin / administration & dosage*,  analogs & derivatives*,  pharmacokinetics,  pharmacology
Reg. No./Substance:
0/Gels; 0/Peptides, Cyclic; 118992-92-0/lanreotide; 12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin; 67763-96-6/Insulin-Like Growth Factor I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional ...
Next Document:  Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis.